Clinical trials: Advanced Digestive System Carcinoma
Liver Cancer
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00467194
- Testing
- Rapamycin, Bevacizumab
- Where
- 2 sites in Singapore
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
- Trial name
- HCC (NCT03398122)
- Testing
- TACE, Apatinib
- Where
- China
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma, Atezolizumab-bevacizumab
Ate-Bev Early Response Prediction Model in Advanced HCC
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation
- Trial name
- NCT05763277
- Testing
- Early response evaluation
- Where
- South Korea
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Tumor Immunity, Immunosuppression
RFA Plus Carrizumab vs Carrizumab Alone for HCC
The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
- Conditions
- Tumor Immunity, Immunosuppression, Radiofrequency Ablation
- Trial name
- NCT04150744
- Testing
- radiofrequency ablation
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
- Trial name
- NCT05469061
- Testing
- Tislelizumab, 5-FU, cis Platinum
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colon Cancer
Screening and Risk Factors of Colon Neoplasia
The investigators propose a screening population-based study to systematically evaluate the accuracy and clinical relevance of sDNA testing as a potential alternative to colonoscopy screening.
- Trial name
- NCT01647776
- Testing
- Stool DNA Test, biopsies of rectal and colon mucosa, Questionnaires
- Where
- United States
- Volunteers
- 3,315 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center